Our weekly newsletter provides unparalleled data, insights and intelligence on the global psychedelics industry, straight to your inbox. Find the latest commercial deals, understand the latest regulatory changes and discover the most impactful scientific discoveries.
Awakn Life Sciences lists on the NEO Exchange; examining psychedelic revenue opportunities within tight regulations; IPOs build momentum as atai Life Sciences goes public. Read more in Issue 34 of The Psychedelics Newsletter.
Examining the business impact of North American psychedelic drug regulations; atai Life Sciences targets US$2.3 billion IPO valuation; and democrats introduce a bill to end the War on Drugs. Read more in Issue 33 of The Psychedelics Newsletter.
For-profit or non-profit? That is the ($100-billion) question. Rick Doblin and Christian Angermayer join the 7 July PSYCH Investor Summit: Research and Development to discuss the role of non and for-profit businesses in a can’t-miss conversation. Read more in Issue 31 of The Psychedelics Newsletter.
Dr. Carl Hart on the impediment of prolonged research; Field Trip appoints former US Senate Majority Leader as Special Adviser and Cybin studies sublingual psilocybin for major depressive disorder. Read more in Issue 30 of The Psychedelics Newsletter.
Announcing the next PSYCH Investor Summit: Research & Development, MindMed hits the NASDAQ and exploring the use of psychedelics to treat addiction. Read more in Issue 26 of The Psychedelics Newsletter.
Exploring the potential to create ethical psychedelics companies, a DNA test to inform psychedelic therapies, and preparing for the PSYCH Investor Summit: Europe and Asia. Read more in Issue 23 of The Psychedelics Newsletter.